



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/443,986	11/19/1999	DANIEL JOSEPH OMAHONY	99.1064.US	8043

7590

09/24/2002

MARY L SEVERSON PH.D. ESQ
ELAN PHARMACEUTICAL RESEACH CORP
1300 GOULD DRIVE
GAINESVILLE, GA 30504

EXAMINER

CARLSON, KAREN C

ART UNIT

PAPER NUMBER

1653

DATE MAILED: 09/24/2002

18

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT

PAPER

18

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

This Office Action is in response to Paper # 17, filed July 8, 2002, and the sequence listing filed June 28, 2002.

The communication filed June 28, 2002 is not fully responsive to the Office communication mailed January 2, 2002 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or Raw Sequence Listing Error Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the above-mentioned reply appears to be bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of ONE (1) MONTH from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

APPLICANTS SHOULD SEND THE DISK TO THE ARLINGTON ADDRESS HIGHLIGHTED ON THE CFR PROBLEM REPORT. APPLICANTS APPEAR TO BE SENDING THE DISK TO THE DC ADDRESS, WHEREIN THE DISK PASSES THROUGHT THE POST OFFICE'S BRENTWOOD FACILITY WHERE IT IS IRRADIATED FOR ANTHRAX AND THEREBY DAMAGED.

Also noted is that Applicants have submitted amendments wherein the amino acid sequence is provided using the single letter code rather than the triple letter code as required under 37 CFR 1.821. Correction of these and any other single letter reference to amino acids is required

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D., whose telephone number is (703) 308-0034. The examiner can normally be reached Monday-Friday from 6:30 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, Ph.D., can be reached on (703) 308-2923. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

KAREN COCHRANE CARLSON, PH.D.
PRIMARY EXAMINER